Entresto Approval History
- FDA approved: Yes (First approved July 7th, 2015)
- Brand name: Entresto
- Generic name: sacubitril and valsartan
- Dosage form: Tablets
- Previous name: LCZ696
- Company: Novartis Pharmaceuticals Corporation
- Treatment for: Heart Failure
Entresto (sacubitril and valsartan) is a neprilysin inhibitor and angiotensin II receptor blocker combination indicated to reduce the risk of death and hospitalization in patients with chronic heart failure.
FDA Approval: The approval of Entresto was based on results from the 8,442-patient PARADIGM-HF study which was stopped early when it was shown Entresto significantly reduced the risk of cardiovascular death and hospitalizations related to heart failure versus ACE-inhibitor enalapril. Analysis of safety data showed that Entresto had a similar tolerability profile to enalapril.
Mechanism: Entresto contains a combination of sacubitril, a first-in-class neprilysin inhibitor, and valsartan, an angiotensin II antagonist already FDA approved as Diovan. It works by reducing the strain on the failing heart.
Administration: Entresto tablets are taken twice daily, usually in conjunction with other heart failure medicines.
Side Effects: Common side effects observed in clinical trial participants being treated with Entresto were low blood pressure (hypotension), high blood potassium levels (hyperkalemia), and poor function of the kidneys (renal impairment).
Additional Information: Angioedema has been reported as a serious side effect of Entresto, and patients are advised to seek emergency medical assistance if they experience symptoms such as trouble breathing.
Development History and FDA Approval Process for Entresto
Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.